





ATC codes: **J05AG03**

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified <b>ICD11 code: 1C62.Z</b>
INN	Efavirenz
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 600 mg tablet (EML)
EML status history	First added in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2017 ( <a href="#">TRS 1006</a> ) Changed in 2021
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <a href="#">about patents.</a> 
Wikipedia	<a href="#">Efavirenz</a> 
DrugBank	<a href="#">Efavirenz</a> 

### Expert Committee recommendation

The Expert Committee recommended deletion of efavirenz 200 mg tablets from the core list of the EML and EMLc. The Committee considered the rationale behind the proposed deletion to be reasonable, and that removal of this formulation would ensure full alignment between the Model Lists and recommendations included in the most recent WHO antiretroviral treatment guidelines and the Optimal Formulary And Limited-Use List For Antiretroviral Drugs For Children.

